Join our daily newsletter At The Bell to receive exclusive market insights
- Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April
- This marks an 11 per cent increase from the 1617 prescriptions in March and brings the total MediCabilis orders filled in FY21 to 9519
- Of the orders filled in April, 64 per cent of the prescriptions were repeat orders
- This growth is based on the ongoing engagement and strong relationships with prescribers, physicians and healthcare professionals
- Bod is up a healthy 18.9 per cent on the market and shares are trading at 44 cents
Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April.
This marks an 11 per cent increase from the 1617 prescriptions in March and brings the total MediCabilis orders filled in FY21 to 9519.
Of the orders filled in April, 64 per cent of the prescriptions were repeat orders.
This growth is based on the ongoing engagement and strong relationships with prescribers, physicians and healthcare professionals.
Since prescriptions first began in 2019, 13,624 MediCabilis units have been sold.
“MediCabilis volumes continue to grow at a very pleasing rate and the recent prescription sales growth further highlight’s Bod’s ability to generate strong revenues across one of the company’s two core operating divisions,” CEO Jo Patterson commented.
“The company continues to maintain a solid segment of the total Australian market through Special Access Scheme Category B,” she said.
“The company has a number of new products in the pipeline that will be launched imminently. We anticipate that the introduction of new products and scale up of operations across both business divisions will unlock considerable value for shareholders,” she added.
Bod is up a healthy 18.9 per cent on the market and shares are trading at 44 cents at 1:50 pm AEST.
